UKPDS and the Legacy Effect
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The United Kingdom Prospective Diabetes Study (UKPDS) continues to produce important evidence concerning the evolution of type 2 diabetes and its management. Two studies published in this issue of the Journal provide some answers to two questions of fundamental importance to patients with diabetes and to physicians alike. In one article, Holman et al. (UKPDS 80)1 provide data that confirm a so-called legacy effect associated with intensive glucose control in patients with type 2 diabetes, long after the cessation of randomized intervention. This finding provides a fitting parallel to the observations of the Diabetes Control and Complications Trial/Epidemiology of Diabetes . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Up to 25% of persons with T2D have already developed at least 1 microvascular complication by the time of diagnosis.40,41”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [40]
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Self-citationLong-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762
Research works printed but not linked: 2
- 10.1056/nejmoa0806359 · DOI · Paper page
- 10.1056/nejmoa0806470 · DOI · Paper page
Cited by
Items 201–271 of 271
Glycaemic Control and Protection of the Vasculature from Glucose Toxicity
Ding, H., & Chris, R. B. (2011) · InTech eBooks · doi:10.5772/24862 · Cited by 2
Pathogenic Features of Insulin Resistance and Critical Organ Damage in the Liver, Muscle and Lung
Nakajima, K., Muneyuki, T., Siato, M., & Kakei, M. (2011) · InTech eBooks · doi:10.5772/20703 · Cited by 2
Advanced Glycation End Products Inhibitor
Dan, T., de Strihou, C. V. Y., & Miyata, T. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-857-7_20 · Cited by 2
“Further studies indeed published in 2008 (ACCORD, VADT, UKPDS posttrial) [ 10 , 11] highlight the existence of an AGE-related metabolic memory in type 2 diabetes.”
BackgroundWang, N., Zoungas, S., & Chalmers, J. P. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104160 · Cited by 3
Self-citationGrosso, A. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_17 · Cited by 2
Jurado, J. (2009) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 9
Sales, A. M. S., Ferreira, J. G., Vasco, R. F. V., & Albuquerque, E. V. D. A. (2024) · HSJ. · doi:10.21876/hsjhci.v14.2024.e1500 · Cited by 1
“…of the therapeutic approach because the control of these laboratory parameters is essential for preventing the progression of the disease and its micro-and macrovascular complications, and good early control of the disease has a legacy effect on the prevention of future complications 10-12 .”
BackgroundThe Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review
Luca, S. A., Bungau, R. M., Lazăr, S., Herascu, A., Gaiţă, L., Avram, V. F., & Timar, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196877 · Cited by 1
“However, while results showed a potential benefit in terms of macrovascular outcomes like CV events, they lacked statistical significance, suggesting that additional factors besides glucose control should be considered in reducing the risk of CVDs in T2D patients [15].”
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2025) · Journal of Clinical Medicine Research · doi:10.14740/jocmr6370 · Cited by 1
“…Prospective Diabetes Study (UKPDS) demonstrated a legacy effect of early, intensive metformin therapy for type 2 diabetes in overweight patients, where the reduction in myocardial infarction and death from any cause persisted even after the trial concluded and glycemic differences were lost [233].”
Russo, G. T., Nicolucci, A., Cuttone, A., Ceriello, A., Manicardi, V., Rocca, A., Prattichizzo, F., Lucisano, G., Corrao, S., Cosmo, S. D., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02599-9 · Cited by 1
Stress and Coping in Adults with Type 2 Diabetes Who Initiate Insulin Therapy
Loft, M. (2015) · Scholarship@Western (Western University) · Cited by 1
Pastromas, S. C., Koulouris, S. N., & Manolis, A. S. (2010) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v5i4.215 · Cited by 1
“A plausible explanation is that the long-term intensive therapy reduces both hyperglycemia and formation of advanced end glycation products.(10) However, a recent study clearly showed that the contribution of hyperglycemia to cardiovascular risk is much greater in T1DM than in T2DM.”
BackgroundDiabetes Control and Cardiovascular Risk, Part II: Intensive Glucose Control – UKPDS Follow‐Up
Liebson, P. R. (2009) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.00020.x · Cited by 1
La supresión de la educación especializada empeora el control metabólico en diabetes tipo 2
Jurado, J., Ros, J. C., Anguera, J. M. H., Canal, D. J., & Torelló, J. M. P. (2009) · Atención Primaria · doi:10.1016/j.aprim.2009.02.014 · Cited by 10
Joshi, R., de Galan, B. E., Chalmers, J. P., Perkovic, V., & Patel, A. A. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.4.2.111 · Cited by 1
Self-citationComparison of Swarm Optimization and Genetic Algorithm for Mobile Robot Navigation
Ćurković, P., Jerbić, B., & Stipanĉić, T. (2010) · InTech eBooks · doi:10.5772/8601 · Cited by 1
Chandalia, H. B., & Thadani, P. (2016) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-016-0467-8 · Cited by 1
Li, S., Zhou, X., Jo, E., Mahzari, A., Fouda, S., Li, D., Zhang, K., & Ye, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181873 · Cited by 1
Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?
Knudsen, S. T., & Cooper, M. E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13917 · Cited by 3
“AGEs represent long-lasting post-translational molecular modifications induced by hyperglycaemia that are involved in the development of late complications in diabetes mellitus,(27) and may constitute part of the explanation for the “legacy effect” of poor glycaemic control over years or even decades.(19,30)”
BackgroundSelf-citationPatsan, I., Tapley, A., Davoren, P. M., Fielding, A., Holliday, E. G., Ball, J., Davey, A., van Driel, M., Turner, R., Mulquiney, K. J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280668 · Cited by 1
Шамхалова, М. Ш., & Sukhareva, O. Y. (2023) · Diabetes Mellitus · doi:10.14341/dm13079 · Cited by 1
Guillausseau, P.-J. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0227-6 · Cited by 1
From Synthalin to Metformin:is a Century Cycle of Biguanides as Oral Antidiabetic drugs Now Closed?Preprint
Ramadori, G. P. (2023) · Preprints.org · doi:10.20944/preprints202307.1299.v1 · Cited by 1
Innovative Approach to Treatment of the Metabolic Syndrome
Ricci, J., Timoney, M., & FERZLI, G. S. (2012) · Springer eBooks · doi:10.1007/978-3-642-02411-5_10
Peripheral vascular and cerebrovascular disease in diabetes mellitus
Mukherjee, D. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch75 · Cited by 2
Understanding the performance of decision strategies in dynamic environments.
Meyer, G. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Dipeptidyl-Peptidase-4-Hemmer und Herzinsuffizienz
Vardarli, I., & Özcelik, C. (2014) · Der Kardiologe · doi:10.1007/s12181-014-0628-2
A Role for Epigenetic Modulation of the Innate Immune Response During Aging
Killick, J., Bennett, S. J., Dias, I. H. K., Dunston, C. R., & Griffiths, H. R. (2013) · Springer eBooks · doi:10.1007/978-3-642-39495-9_4
Meece, J. D., Pearson, T. L., & Siminerio, L. M. (2014) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721714527802
Nauwkeurige glycaemische en tensiecontrole bij diabetes type 2, effecten op de lange termijn
de Klaver, P. (2009) · Medisch-Farmaceutische Mededelingen · doi:10.1007/bf03079940
Bad Medicine: There Is a Lot Wrong with Diabetes Care in the United States
Sheehan, J. P. (2010) · Culture Medicine and Psychiatry · doi:10.1007/s11013-009-9158-y
Paying for Performance: Key Design Features and the Bigger Picture
Ryan, P. (2012) · International Journal of Public and Private Healthcare Management and Economics · doi:10.4018/ijpphme.2012040101
Utilization Of Oral Anti-diabetic Medications: Examining Adherence To Clinical Guidelines
Rao, S. (2011) · Figshare
The Vasculature in the Diseased Eye
Hammes, H. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2907-8_12
Alenezi, H. S., Kharal, M., Yousuf, M., Al‐Saleh, Y., & Salih, S. B. (2013) · Saudi Journal of Internal Medicine · doi:10.32790/sjim.2013.3.1.5
Respuesta del Dr. Domingo Ly Pen
Ly‐Pen, D. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)63013-x
Chen, Z., Gao, W., & Ying, W. (2012) · The Chinese Journal of Modern Applied Pharmacy
Das metabolische Gedächtnis und Diabetes-assoziierte Komplikationen
Pavlicek, V. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0491-7
Diabetic Peripheral Neuropathies (DPNs) from Basic and Clinical Aspects
Bando, H. (2019) · Journal of Obesity and Diabetes · doi:10.33805/2638-812x.116
“Further, Impaired Glucose Tolerance (IGT) may exacerbate the pathophysiological changes of neuropathy as an indicator of small-fiber influence [11-13].”
BackgroundYong, J., Tian, J., Cao, J., Kong, H., Zhao, X. Y., Yang, X., He, Y., & Song, X. (2021) · Research Square · doi:10.21203/rs.3.rs-814521/v1
Geba, D. (2018) · UR Research (University of Rochester)
Unsolved pharmacological issues with cardiology
Agewall, S. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab077
Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch14
Abeyaratne, D., Priya, G., Kalra, S., Aye, T. T., Aung, M. W., & Sumanatilleke, M. (2019) · Journal of Social Health and Diabetes · doi:10.1055/s-0039-1683468
Aronow, W. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735910698.793566214
Darmian, M. A., Hoseini, R., Amiri, E., & Golshani, S. (2022) · Journal of Kermanshah University of Medical Sciences · doi:10.5812/jkums-115917 · Cited by 1
“The primary goal of HD management is achieving higher levels of QoL and preventing the onset of comorbidities (10).”
BackgroundEpigenomics of Type 2 Diabetes
Parveen, A. N., & Dhawan, B. S. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165498-00053
Raja, S. A., Aye, M. T. H., Mani, B. I., Tan, J. C., & Chong, V. H. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e44
Diabetic kidney disease: Risk factors, challenges and opportunities in the era of precision medicine
khan, S., Nayak, S. P. S., Sen, S., Kumar, D., Verma, V. K., Patel, D. D., & Chakraborthy, G. S. (2023) · International Journal of Biological and Pharmaceutical Sciences Archive · doi:10.53771/ijbpsa.2023.5.2.0027
Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes
Jenkins, A. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_29
Rybachuk, O. V. (2024) · Medical Science of Ukraine (MSU) · doi:10.32345/2664-4738.2.2024.01
Shaikh, N., Qureshi, N., Qureshi, M. J., Mian, Z. R., Saeed, H., Rana, M. A., & Ali, M. A. (2025) · Cureus · doi:10.7759/cureus.92853 · Cited by 1
“Multivariate analysis revealed a mean BMI of 29.2 kg/m² in the high-adherence group versus 32.0 kg/m² in the low-adherence group [25].”
InfluentialFukaguchi, K., Shinozaki, T., Narita, Z. C., & Goto, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113020
Anti-diabetic effects of oleanolic acid and matrine
Zeng, X. (2014) · RMIT Research Repository (RMIT University Library) · doi:10.25439/rmt.27351540
Understanding the Specific Influence of Mitochondria on Cellular Health in Diabetes
Dolinko, A. H. (2021) · eScholarship (California Digital Library)
Reboldi, G. (2009) · Giornale Ialiano di Cardiologia · doi:10.1714/582.6879
“Questo risultato ha aperto un’interessante discussione sul feno-meno denominato “memoria metabolica” da alcuni rite-nuto un reale, non solo potenziale, disease modifier 17 .”
Acsl1-Mediated Fatty Acid Synthesis Impairs Osseointegration in Type 1 Diabetes
Zheng, X. H., Zhu, X. Y., Chen, X., He, Q. Q., Zhai, Q., & Chen, T. (2026) · Journal of Dental Research · doi:10.1177/00220345261430286 · Cited by 1
“Paradoxically, emerging evidence indicates that even when normoglycemia is subsequently achieved, prior exposure to hyperglycemia leaves a durable “legacy effect” (Chalmers and Cooper 2008; Newman et al 2018; Sundar et al 2019; Del Cuore et al 2023).”
The doxastic relevance of imagination in the common sense model of illness representations
Brecevic, C. (2026) · Synthese · doi:10.1007/s11229-026-05715-6
“This effect (also called metabolic memory) refers to the positive effect early glycemic control has on future outcomes among T2DM patients (Chalmers & Cooper, 2008).”
Introduction to metabolic memory
Gupta, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44591-0.00013-8
Prato, S. D., Genovese, S., Galeone, C., Mariani, P., Acquaviva, T., Antonutti, M., Anzaldi, M., Bucciarelli, L., Carleo, D., Cesaro, A., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02770-w
“Early intervention is crucial to counteract the so called “metabolic memory”, defined as the establishment of cel - lular processes due to initial poor metabolic control that limit the beneficial effects of subsequent improvements in the metabolic milieu achieved through treatment [12, 24].”
鱶口, 清. (2026) · Institutional Repositories DataBase (IRDB)
Zhang, J. R., Singh, P., Yeung, R. O., Manca, D. P., Perry, T., Olu-Jordan, I., Rahim, G., Hagen, E. M., & Lau, D. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.09.007
Monami, M., Giorgino, F., Borghi, C., Ragghianti, B., Guglielmi, V., & Sbraccia, P. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70238
“An intensive glycaemic management reduced microvascular complications and generated long‐term reductions in myocardial infarction and all‐ cause mortality during post‐trial follow‐up, a phenomenon later described as the legacy effect [7–9].”
Metadata
- Authors
- Chalmers, J., & Cooper, M. E.
- Affiliations
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1618-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1966627775
- Cited by
- 263
- References
- 9
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 15 · 2023: 25 · 2022: 14 · 2021: 22 · 2020: 15 · 2019: 18 · 2018: 6 · 2017: 12 · 2016: 14 · 2015: 16 · 2014: 16 · 2013: 10 · 2012: 18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- legacy effects, tight glycemic control, type 2 diabetes, long-term glycemic control, diabetes management, UKPDS
- MeSH terms
- Antihypertensive Agents, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Insulin, Sulfonylurea Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.